Savara Inc. is a Texas-based biopharmaceutical company that specializes in addressing rare respiratory diseases. Their primary product candidate, molgramostim, aims to treat autoimmune pulmonary alveolar proteinosis and is currently in Phase III development. The company is in its clinical stage and primarily focuses on advancing its lead product.